Related Experiment Video
Updated: Jun 11, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial
Sandi Culo1, Benoit H Mulsant, Jules Rosen
1*Department of Psychiatry, University of British Columbia, Vancouver †Department of Psychiatry, Centre for Addiction and Mental Health, and University of Toronto ∥Rotman Institute, Baycrest, Toronto, Canada ‡Departments of Psychiatry, Western Psychiatric Institute and Clinic §Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh.
Abstract:
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and 66 with AD hospitalized for behavioral disturbance were treated under randomized, double-blind conditions with citalopram or risperidone for up to 12 weeks. Neuropsychiatric symptoms were assessed with the nursing home version of the Neuropsychiatric Inventory (NPI) and the Clinical Global Impression of Change (CGIC). Side effects were measured using the UKU Side Effect Rating Scale. A significantly higher proportion of participants with DLB (68%) than with AD (50%) discontinued the study prematurely. Discontinuation rates were comparable in DLB participants treated with citalopram (71%) or risperidone (65%). However, participants with DLB randomized to risperidone experienced a higher overall burden of side effects. Scores on the NPI and the CGIC worsened in DLB participants and improved in those with AD. Most patients with behavioral disturbances or psychosis associated with DLB tolerate citalopram or risperidone poorly and do not seem to benefit from either medication.
Related Concept Videos
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia
The progression of dementia is generally gradual.
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Dementia l: Introduction